soul trial oral semaglutide cardiovascular outcomes soul trial results Forecasting Milestones: A Predictive Analysis for Early Termination of the Study | Diabetes Therapy European - 📢 🎤 Everything

Using up-to-date prescription and dispense data, we will continue to monitor uptake, treatment patterns, and outcomes of novel medications to treat obesity

Side effect profiles are broadly similar across all three

5 , 6 In contrast, some agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, may be advantageous with respect to improved renal outcomes with SGLT2 inhibitors as well as improved cardiovascular (CV) outcomes with both of these classes of medications, which is a particular concern as CV effects are common and a leading cause of death among those with diabetes

B , Cumulative TAM consumed in milligrams (mg) by sex ( n = 2 cages/sex)